Thanks for that. I was wondering about this: "There were some imbalances in baseline patient characteristics across the treatment arms in CUPID 1. In particular, there was a higher percentage of healthier patients in Mydicar arms relative to placebo arms. Post-hoc sensitivity analyses though suggested that the differences in baseline patient characteristics could not completely explain the clinical outcomes observed in CUPID 1. "
Celladon is almost at the price target now. Might explore this as a short candidate. A quick EDGAR search shows no bailing by insiders or holders so far, and I assume lockup period is over.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.